Cytyc (Marlborough, Massachusetts) said that the North Carolina State Laboratory of Public Health (SLPH) is the first state public health laboratory to convert to the ThinPrep Imaging System for all cervical cancer screening.

This builds on the laboratory's use of the ThinPrep Pap Test, which began in 1999. The lab currently processes approximately 110,000 Pap tests annually. The SLPH provides medical and environmental laboratory services to public health organizations including county health departments.

The ThinPrep Imaging System is the first fully integrated, interactive computer system that assists cytotechnologists and pathologists in the primary screening and diagnosis of ThinPrep Pap Test slides, the company said.

Nasdaq denies Applied Imaging appeal

Applied Imaging (San Jose, California) reported its receipt of a Nasdaq Listing Qualifications Panel decision denying the company's appeal of a Nasdaq staff determination on Dec. 9, which found that the company failed to comply with the stockholders' equity requirement for continued listing set forth in Nasdaq Marketplace Rule 4310(c)(2)(B).

As a result, Applied Imaging's securities were withdrawn from the Nasdaq Capital Market effective with the opening of business on Wednesday.

The company has 15 days from Jan. 23 to request a review of the panel's decision by the Nasdaq Listing and Hearing Review Council, and is considering this option.

Applied Imaging is a supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications.

Ciphergen in compliance with Nasdaq

Ciphergen Biosystems (Fremont, California) said that the Nasdaq Listing Qualifications Panel has informed the company that it has evidenced compliance with the requirements for continued listing on the Nasdaq National Market and that the "E" that has been appended to the company's ticker symbol was removed effective at the opening of business Jan. 25.

Ciphergen is dedicated to the discovery of protein bio-markers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays.

Ciphergen makes a family of ProteinChip Systems and services for clinical, research and process proteomics applications.

No Comments